Report Content
Chapter 1 Methodology & Scope
1.1 Methodology
1.2 Market scope and definition
1.3 Base estimates and working
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Stem cell therapy industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Type trends
2.1.3 Therapeutic area trends
2.1.4 End-use trends
2.1.5 Regional trends
Chapter 3 Stem Cell Therapy Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2018 - 2032
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Advancements in regenerative medicine in North America & Europe
3.3.1.2 Increasing government initiatives for stem cell therapy in developed as well as developing countries
3.3.1.3 Rising awareness regarding availability of stem cell therapy in developing countries
3.3.1.4 Growing prevalence of chronic diseases
3.3.1.5 Increasing research and development activities undertaken by companies for stem cell therapy
3.3.2 Industry pitfalls & challenges
3.3.2.1 High cost of stem cell therapy
3.3.2.2 Ethical issues associated with stem cell therapy
3.4 Growth potential analysis
3.4.1 By type
3.4.2 By therapeutic area
3.4.3 By end-use
3.5 COVID-19 impact analysis
3.6 Stem cell therapy ecosystem analysis
3.7 Regulatory landscape
3.7.1 U.S.
3.7.2 Europe
3.7.3 Asia Pacific
3.8 Stem cell source
3.8.1 Mesenchymal stem cells (MSCs)
3.8.2 Hematopoietic stem cells (HSCs)
3.8.3 Embryonic stem cells (ESCs)
3.8.4 Induced pluripotent stem cells (iPSCs)
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategy dashboard
Chapter 5 Stem Cell Therapy Market, By Type
5.1 Key type trends
5.2 Allogenic stem cell therapy
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Autologous stem cell therapy
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Stem Cell Therapy Market, By Therapeutic Area
6.1 Key therapeutic area trends
6.2 Oncology
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Orthopedic
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Cardiovascular
6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.5 Neurology
6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.6 Orthopedic
6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Stem Cell Therapy Market, By End-use
7.1 Key end-use trends
7.2 Hospitals
7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 Clinics
7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.4 Orthopedic
7.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Stem Cell Therapy Market, By Region
8.1 Key regional trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Russia
8.3.7 Poland
8.3.8 Switzerland
8.3.9 Netherlands
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Thailand
8.4.7 Singapore
8.5 Latin America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Mexico
8.5.4 Chile
8.6 Middle East & Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Israel
Chapter 9 Company Profiles
9.1 Astellas Pharma Inc
9.2 CHIESI Farmaceutici S.p.A.
9.3 Capricor Therapeutics
9.4 Cellectis
9.5 Fujifilm Cellular Dynamics
9.6 GSK plc.
9.7 ThermoGenesis Holdings, Inc
9.8 DiscGenics
9.9 Mesoblast Ltd
9.10 Novadip Biosciences
9.11 MEDIPOST
9.12 Takeda Pharmaceuticals
9.13 Celyad
9.14 Gamida Cell
9.15 ReNeuron Group plc
